TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 08 2021 - 7:00AM
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael
S. Weiss, the Company’s Executive Chairman and Chief Executive
Officer, will present at the 39th Annual J.P. Morgan Healthcare
Conference, being held virtually. The presentation is scheduled to
take place on Tuesday, January 12, 2021 at 2:00 PM ET.
A live webcast of this presentation will be available on the
Events page, located within the Investors & Media section, of
the Company’s website at http://ir.tgtherapeutics.com/events. A
replay of the webcast will be available on TG’s website following
the event.
ABOUT TG THERAPEUTICS, INC.TG
Therapeutics is a biopharmaceutical company focused on the
acquisition, development and commercialization of novel treatments
for B-cell malignancies and autoimmune diseases. Currently, the
company is developing multiple therapies targeting hematological
malignancies and autoimmune diseases. Ublituximab (TG-1101) is a
novel, glycoengineered monoclonal antibody that targets a specific
and unique epitope on the CD20 antigen found on mature
B-lymphocytes. TG Therapeutics is also developing
umbralisib (TGR-1202), an oral, once-daily dual inhibitor of
PI3K-delta and CK1-epsilon. Umbralisib is currently under review by
the U.S. Food and Drug Administration (FDA) for
accelerated approval as a treatment for patients with previously
treated marginal zone lymphoma (MZL) who have received at least one
prior anti-CD20 based regimen or follicular lymphoma (FL) who have
received at least two prior systemic therapies. Both ublituximab
and umbralisib, or the combination of which is referred to as "U2",
are in Phase 3 clinical development for patients with hematologic
malignancies, with ublituximab also in Phase 3 clinical development
for Multiple Sclerosis. Additionally, the Company has recently
brought into Phase 1 clinical development its anti-PD-L1 monoclonal
antibody, cosibelimab (TG-1501), its Bruton’s Tyrosine Kinase (BTK)
inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific
antibody, TG-1801. TG Therapeutics is headquartered
in New York City.
CONTACT:
Jenna A. Bosco
Senior Vice President,
Corporate
Communications
TG Therapeutics,
Inc.
Telephone:
212.554.4351
Email:
ir@tgtxinc.com
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Sep 2023 to Sep 2024